You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

0

0

Game starts at 7:10 PM

Letters

Think twice about how we let overseas use of Plan B guide us

“Morning-after pill” on display at a California pharmacy.

Justin Sullivan/Getty Images/File

“Morning-after pill” on display at a California pharmacy.

In “Plan B, and politics of parenthood” (Op-ed, April 14) Joan Vennochi offers a refreshingly nuanced view on US District Court Judge Edward Korman’s ruling which requires the Food and Drug Administration to lift age restrictions on the so-called morning-after pill.

In striking down age limits on Plan B, Korman sharply criticized Health and Human Services Secretary Kathleen Sebelius’ decision in 2011 to keep teens age 16 and under from buying Plan B over the counter, calling it “arbitrary, capricious, and unreasonable.” Presumably referring to its use by teens overseas, Korman suggested that the hormonal agent was “among the safest drugs sold OTC.”

Continue reading below

Here, Korman is falling victim to a widespread misperception that, because some industrialized nations have made Plan B available behind the counter to teens without a prescription, it is sufficiently safe and effective to be used over the counter. Behind the counter and over the counter are qualitatively different.

Behind the counter implies that dispensing of Plan B involves a learned intermediary to instruct the person who is requesting access to the product that the agent is not and should not be used as a routine birth control method. Moreover, in Britain, a country known for its relatively liberal policies on availability of drugs without a prescription, Plan B can only be sold behind the counter to people over 16.

Surely, the decisions by overseas health authorities to make Plan B available behind the counter and to impose age restrictions were not arbitrary, capricious, or unreasonable.

Joshua Cohen

Boston

The writer is senior research fellow with the Tufts Center for the Study of Drug Development.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.